GEN Exclusives

More »

GEN News Highlights

More »
Aug 28, 2012

EC Clears First Myelofibrosis Drug

  • Novartis’ Jakavi® (ruxolitinib, INC424) has become the first drug to be approved by the EC for treating myelofibrosis. Regulatory clearance in Europe covers use of the JAK1/2 inhibitor for treating disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.

    Novartis’ holds a license from Incyte to develop and commercialize ruxolitinib in all global territories outside the U.S., for all hematology-oncology indications. Incyte retains U.S. rights to the drug (trade-named Jakafi®), which was approved by FDA in November 2011 for treating intermediate or high-risk myelofibrosis, including primary myelofibrfosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.

    Approval of Jakavi in Europe was based on a clinical program including two pivotal Phase III trials, Comfort-1 and Comfort-II, which demonstrated that the drug led to statistically significant reductions in spleen volume and myelofibrosis symptoms from baseline when compared with either placebo or best available therapy.

    "This approval marks a significant milestone in addressing unmet treatment needs for patients in the European Union," remarks Hervé Hoppenot, president, Novartis Oncology. "We are committed to the development of innovative treatments for orphan diseases, and are furthering research to assess the potential of targeted Jakavi therapy for other malignancies associated with a dysregulated JAK pathway."

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »